Neuro-Oncology

An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.

Neuro-Oncology

Lal S, Carrera D, Phillips JJ, Weiss WA, Raffel C

Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Neuro-Oncology

Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Neuro-Oncology

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA

Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Neuro-Oncology

Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Neuro-Oncology

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM

Magnetic resonance analysis of malignant transformation in recurrent glioma.

Neuro-Oncology

Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, Berger MS, Chang SM, Nelson SJ

Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.

Neuro-Oncology

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Yeh I, Bastian BC, Mueller S, Solomon DA

Toward precision medicine in glioblastoma: the promise and the challenges.

Neuro-Oncology

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM

A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

Neuro-Oncology

Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD

Pages